Natalie B Simon1, Michael A Danso2, Thomas A Alberico3, Ethan Basch4, Antonia V Bennett5. 1. College of Arts and Sciences, University of Virginia, 1521 Virginia Ave. Apt. 1, Charlottesville, VA, 22903, USA. nbs5hw@virginia.edu. 2. Department of Medical Oncology and Hematology, Virginia Oncology Associates, Norfolk, VA, USA. 3. Department of Stem Cell Transplant, Medical Oncology, and Hematology, Virginia Oncology Associates, Norfolk, VA, USA. 4. Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 5. Department of Health Policy and Management, University of North Carolina, Chapel Hill, NC, USA.
Abstract
PURPOSE: To describe the prevalence, severity, and risk factors of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on function and quality of life (QOL) among women treated for breast cancer in a large U.S. Community Oncology practice. METHODS: Women previously treated with taxane-based chemotherapy for early-stage breast cancer completed the EORTC QLQ-C30, QLQ-BR23, and QLQ-CIPN20. Subscales are scored 0-100; higher scores indicate greater symptom severity. Pre-specified hypotheses were tested. RESULTS: 126 women with mean age 56.7 years (SD 11.8) were stage I-II (79.4%) or stage III (20.6%) at the time of the survey; 65.1% were White and 27.8% were Black or African American. The mean time since last taxane chemotherapy cycle was 144.9 weeks (SD 112.9). 73.0% reported having CIPN. QLQ-CIPN20 mean scores for the sensory, motor, and autonomic subscales were 18.9 (SD 23.1), 18.6 (SD 18.7), and 17.1 (SD 21.8), respectively. CIPN symptom severity was negatively correlated with global health status/QOL and physical and role functioning (range of r = -0.46 to -0.72). It was not associated with age, body mass index, diabetes, or cumulative taxane dosage, but was greater for Black or African American women (e.g., sensory, p < 0.002). CIPN sensory impairment was marginally greater for patients treated with paclitaxel compared to docetaxel (p < 0.064). CONCLUSIONS: CIPN was prevalent in this community oncology practice and significantly impacts function and QOL. These data highlight the importance of developing methods to mitigate CIPN, and for screening for CIPN particularly among Black or African American women.
PURPOSE: To describe the prevalence, severity, and risk factors of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on function and quality of life (QOL) among women treated for breast cancer in a large U.S. Community Oncology practice. METHODS:Women previously treated with taxane-based chemotherapy for early-stage breast cancer completed the EORTC QLQ-C30, QLQ-BR23, and QLQ-CIPN20. Subscales are scored 0-100; higher scores indicate greater symptom severity. Pre-specified hypotheses were tested. RESULTS: 126 women with mean age 56.7 years (SD 11.8) were stage I-II (79.4%) or stage III (20.6%) at the time of the survey; 65.1% were White and 27.8% were Black or African American. The mean time since last taxane chemotherapy cycle was 144.9 weeks (SD 112.9). 73.0% reported having CIPN. QLQ-CIPN20 mean scores for the sensory, motor, and autonomic subscales were 18.9 (SD 23.1), 18.6 (SD 18.7), and 17.1 (SD 21.8), respectively. CIPN symptom severity was negatively correlated with global health status/QOL and physical and role functioning (range of r = -0.46 to -0.72). It was not associated with age, body mass index, diabetes, or cumulative taxane dosage, but was greater for Black or African American women (e.g., sensory, p < 0.002). CIPN sensory impairment was marginally greater for patients treated with paclitaxel compared to docetaxel (p < 0.064). CONCLUSIONS: CIPN was prevalent in this community oncology practice and significantly impacts function and QOL. These data highlight the importance of developing methods to mitigate CIPN, and for screening for CIPN particularly among Black or African American women.
Entities:
Keywords:
Breast cancer; Chemotherapy-induced peripheral neuropathy; Community practice; Disparities; EORTC QLQ–C30; Quality of life; Treatment toxicity
Authors: S E Jones; J Erban; B Overmoyer; G T Budd; L Hutchins; E Lower; L Laufman; S Sundaram; W J Urba; K I Pritchard; R Mennel; D Richards; S Olsen; M L Meyers; P M Ravdin Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2010-12-03 Impact factor: 4.872
Authors: Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse Journal: Support Care Cancer Date: 2014-05-01 Impact factor: 3.603
Authors: Michael D Stubblefield; Harold J Burstein; Allen W Burton; Christian M Custodio; Gary E Deng; Maria Ho; Larry Junck; G Stephen Morris; Judith A Paice; Sudhakar Tummala; Jamie H Von Roenn Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14
Authors: Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park Journal: J Cancer Surviv Date: 2021-01-12 Impact factor: 4.442
Authors: Ciao-Sin Chen; Ellen M Lavoie Smith; Kathleen A Stringer; N Lynn Henry; Daniel L Hertz Journal: Breast Cancer Res Treat Date: 2022-06-28 Impact factor: 4.624
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14
Authors: Hannah C Timmins; Tiffany Li; David Goldstein; Terry Trinh; David Mizrahi; Michelle Harrison; Lisa G Horvath; Michael Friedlander; Matthew C Kiernan; Susanna B Park Journal: J Cancer Surviv Date: 2021-02-27 Impact factor: 4.442
Authors: Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810